Synairgen plc (SNG.L)

5,76 -0,15 (-2,54%) Alla chiusura: 02:04PM BST

Synairgen plc

Mailpoint 810
Level F, South Block Southampton General Hospital Tremona Road
Southampton SO16 6YD
United Kingdom
44 23 8051 2800
https://www.synairgen.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 34

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Richard Marsden	CEO, MD & Executive Director	328k	N/D	1967
Prof. Stephen T. Holgate CBE, M.D.	Co-Founder, Non-Executive Director & Member of Scientific Advisory Board	44k	N/D	1947
Dr. Phillip David Monk	Chairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director	240k	N/D	1969
Prof. Donna Davies	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Prof. Ratko Djukanovic	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Mr. Joseph Tregonning Colliver F.C.A.	CFO & Executive Director	N/D	N/D	1980
Dr. Gareth E. Walters Ph.D.	Chief Regulatory Officer	N/D	N/D	1959
Ms. Jody Brookes	Senior VP & Head of Clinical Operations	N/D	N/D	N/D
Mr. Richard Francis	Senior VP and Head of CMC & Quality	N/D	N/D	N/D
Dr. Victoria Tear	Head of Laboratory	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Synairgen plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.